small molecule

ORSERDU

ELACESTRANT HYDROCHLORIDE

Loss of exclusivityJanuary 2038latest FDA-listed patent expiry

CompanyStemline Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand name	ORSERDU
Active ingredient	ELACESTRANT HYDROCHLORIDE
Strength	EQ 86MG BASE
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	January 2023
Marketing status	RX

Listed patents

Patent	Expires	Type
10745343	January 2038	use U-3523
10385008	January 2038	substance, product
11819480	February 2037	use U-3523
10420734	October 2036	use U-3524
10071066	October 2034	use U-3524
11779552	October 2034	use U-3524
7612114	August 2026	substance, product

Regulatory exclusivity

Code	Expires
NCE	January 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Stemline Therapeutics